2013-05-15T10:40:38-05:00 2012-12-31 560574444 CHERRY BEKAERT LLP 1111 METROPOLITAN AVENUE SUITE 1000 CHARLOTTE NC 28204 990 2012-01-01 010648145 ORTHOCAROLINA RESEARCH INSTITUTE INC FMRLY O L MILLER RESEARCH INSTITUTE ORTH 7043232260 2001 VAIL AVENUE NO 300 CHARLOTTE NC 28207 ANNE SCHWOEBEL 7043232260 2013-05-15 1 JANICE A RATICA P00358837 7043771678 2012 2016-02-24 21:20:13Z CHRISTI CADD 2001 VAIL AVENUE NO 300 CHARLOTTE NC 28207 1261414 0 X WWW.ORTHOCAROLINARESEARCH.ORG X 2002 NC ORTHOCAROLINA RESEARCH INSTITUTE (THE "INSTITUTE" OR "OCRI") IS A NON-PROFIT ORGANIZATION DEDICATED TO PROMOTE, DEVELOP AND CONDUCT STATE OF THE ART SCIENTIFIC RESEARCH AND EDUCATIONAL PROGRAMS FOR THE ADVANCEMENT OF ORTHOPAEDIC CARE. OCRI WAS FOUNDED TO ADVANCE AND IMPROVE ORTHOPAEDIC HEALTHCARE AND FOSTER SCIENTIFIC COLLABORATIONS BETWEEN OCRI, UNIVERSITIES, HOSPITALS, PHARMACEUTICAL COMPANIES, HEALTHCARE DEVICE MANUFACTURERS AND OTHER ACADEMIC AND RESEARCH ORGANIZATIONS. 13 13 14 13 0 0 577797 401738 709928 829927 34708 29749 0 0 1322433 1261414 14100 0 0 0 611866 703174 0 0 24604 451587 524242 1077553 1227416 244880 33998 2011000 2273606 179696 262539 1831304 2011067 X THE INSTITUTE'S MISSION AND PRIORITIES ARE CENTRALLY FOCUSED ON: (1) IMPROVED PATIENT CARE, (2) HIGH QUALITY RESEARCH TO DEVELOP NEW AND INNOVATIVE ORTHOPAEDIC DEVICES AND TECHNOLOGIES, AND (3) COLLABORATIVE AND MULTIDISCIPLINE FORUMS TO FURTHER ENHANCE STATE-OF-THE-ART MEDICAL HEALTHCARE. THE INSTITUTE IS CURRENTLY PARTICIPATING IN 30 ON-GOING FDA REGULATED CLINICAL TRIALS AND APPROXIMATELY 70 SCIENTIFIC OUTCOMES STUDIES. ALL STUDIES SUPPORT THE PUBLIC IN PROVIDING STATE-OF-THE-ART SURGICAL TREATMENTS AND IMPROVED PATIENT CARE. 0 0 988569 829927 CLINICAL TRIALS ARE DESIGNED TO DEVELOP NEW DEVICES, EVALUATE NEW MEDICATIONS, IMPROVE MATERIALS AND SYSTEMS, AND IMPROVE SURGICAL PROCEDURES. AT THE PRESENT TIME, THE ORTHOCAROLINA RESEARCH INSTITUTE IS FACILITATING THIRTY FDA-CONTROLLED CLINICAL TRIALS THAT SERVE AND SUPPORT THE PUBLIC IN PROVIDING STATE-OF-THE-ART SURGICAL AND NON-SURGICAL TREATMENT OPTIONS. SCIENTIFIC OUTCOMES STUDIES ARE DESIGNED TO PROVIDE DATA AND INFORMATION SUPPORTS, AND/OR OPPOSES, NEW METHODS OF TREATMENT, AND DETERMINES NEW TECHNOLOGY IN ORDER TO PROVIDE THE BEST TREATMENT OPTIONS FOR PATIENTS. CLINICAL RESEARCH STUDIES ALLOW PHYSICIANS TO PROVIDE IMPROVED PATIENT CARE, EVALUATE THE RESULTS OF NEW PROCEDURES, INSURE THAT THE TREATMENTS PROVIDED ARE THE BEST AVAILABLE, PROMOTE COST EFFECTIVE TREATMENT PROGRAMS, AND DOCUMENT PATIENT SATISFACTION AND QUALITY OF LIFE.ALL CLINICAL TRIALS AND SCIENTIFIC OUTCOMES STUDIES ARE REVIEWED AND APPROVED BY THE INSTITUTE'S RESEARCH ADVISORY COMMITTEE (RAC), THE INSTITUTIONAL REVIEW BOARD (IRB) AT CAROLINAS HEALTHCARE SYSTEM (CHS) OR PRESBYTERIAN ORTHOPAEDIC HOSPITAL (POH) PRIOR TO IMPLEMENTATION. STRINGENT PROTOCOLS ARE REQUIRED TO ENSURE THE SAFETY OF ALL PARTICIPATING INDIVIDUALS AND TO MAKE CERTAIN THAT PARTICIPATING SURGEONS FOLLOW THE SAME STUDY PROCEDURES AND GUIDELINES. 988569 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 27 0 14 1 0 0 0 0 0 0 0 0 0 0 X 13 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NC X CHRISTI CADD 7043232260 2001 VAIL AVENUE STE 300 CHARLOTTE NC 28207 PATRICK M CONNOR MD 1.00 X 0 0 0 WILLIAM L GRIFFIN MD 3.00 X X 0 0 0 WALTER B BEAVER MD 1.00 X 0 0 0 ROBERT A HEYER MD 1.00 X 0 0 0 MR STEVEN W LUQUIRE 1.00 X 0 0 0 J MICHAEL WATTENBARGER MD 1.00 X 0 0 0 MR JOHN L FRALEY JR 1.00 X 0 0 0 MR FRED R JONES 1.00 X 0 0 0 MORRY JOHNSTON 1.00 X 0 0 0 MR WESLEY WALLS 1.00 X 0 0 0 GLENN GASTON MD 1.00 X 0 0 0 BRUCE E COHEN MD 1.00 X 0 0 0 CHARLES M EAST III 1.00 X 0 0 0 CHRISTI CADD 40.00 X 103721 0 2943 103721 0 2943 1 0 0 0 0 401738 401738 RESEARCH FOR PUBLIC BE 900099 829927 829927 829927 25755 25755 3994 0 3994 3994 3994 1261414 829927 0 29749 106664 59423 47241 455326 455326 13085 11985 1100 83893 76841 7052 44206 40490 3716 8266 8266 15048 15048 12600 12600 13656 13656 41979 41979 8688 8688 15172 15172 STUDY EXPENSES 276957 276957 OSCAR MILLER DAY EXPENS 62924 62924 MISCELLANEOUS 62725 1636 36485 24604 EQUIPMENT 3240 3240 2987 2987 1227416 988569 214243 24604 364349 528523 313503 251469 13878 13878 0 0 1333148 1493614 2011000 2273606 141963 262539 37733 0 179696 262539 X 1831304 2011067 1831304 2011067 2011000 2273606 33998 145765 0 X 0 1 X 1 0 X 155711 219517 372602 577797 401738 1727365 684238 490421 575108 709928 829927 3289622 839949 709938 947710 1287725 1231665 5016987 100711 194517 303121 387926 238758 1225033 0 100711 194517 303121 387926 238758 1225033 3791954 23845 26282 35601 24848 25755 136331 23845 26282 35601 24848 25755 136331 863794 736220 983311 1312573 1257420 5153318 0.73580 0.72060 0.02650 0.03060 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 13878 13878 0 0 FIXED INCOME POOL 256902 F EQUITY POOL 892434 F PRIVATE INVESTMENT FUNDS 344278 F 1493614 X 1231665 0 1231665 29749 29749 1261414 1212368 0 1212368 15048 15048 1227416 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X, LINE 2: THE INSTITUTE IS LIABLE FOR FEDERAL AND STATE TAXES ON ANY UNRELATED BUSINESS INCOME, AS DEFINED IN THE INTERNAL REVENUE CODE. THE INSTITUTE'S POLICY IS TO RECORD A LIABILITY FOR ANY TAX POSITION TAKEN THAT IS BENEFICIAL TO THE INSTITUTE, INCLUDING ANY RELATED INTEREST AND PENALTIES, WHEN IT IS MORE LIKELY THAN NOT THE POSITION TAKEN BY MANAGEMENT WITH RESPECT TO A TRANSACTION OR CLASS OF TRANSACTIONS WILL BE OVERTURNED BY A TAXING AUTHORITY UPON EXAMINATION. MANAGEMENT BELIEVES THERE ARE NO SUCH POSITIONS AS OF DECEMBER 31, 2012 AND 2011 AND, ACCORDINGLY, NO LIABILITY HAS BEEN ACCRUED. THE INSTITUTE IS NO LONGER SUBJECT TO TAX EXAMINATIONS FOR YEARS PRIOR TO 2009. PART XI, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT INCOME SHOWN AS CHANGE IN BENEFICIAL INTEREST TRUST ON FINANCIALS 25,755. REALIZED GAIN SHOWN AS CHANGE IN BENEFICIAL INTEREST IN TRUST ON FINANCIALS 3,994. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 IS EMAILED TO ALL BOARD MEMBERS FOR THEIR REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C DIRECTORS, OFFICERS AND KEY EMPLOYEES CERTIFY THAT THEY READ THE ORGANIZATION'S CONFLICT OF INTEREST POLICY AND HAVE DISCLOSED ANY RELATIONSHIPS WITH ANY OF THE ORGANIZATION'S CONTRACTING PARTIES ON THE ORGANIZATION'S CONFLICT OF INTEREST FORM. THE EXECUTIVE DIRECTOR REVIEWS THESE CERTIFIED FORMS, INCLUDING COMPARISONS TO THE PRIOR YEAR'S DISCLOSURES, AND CONFIRMS ANY CHANGES WITH THE SIGNERS. NO QUESTIONABLE RELATIONSHIP HAS BEEN NOTED OR BROUGHT TO THE ATTENTION OF THE APPROPRIATE GOVERNANCE GROUP. AT THE MAY MEETING OF THE FINANCE/AUDIT COMMITTEE, THE EXECUTIVE DIRECTOR REVIEWS WITH THE COMMITTEE THE COMPLIANCE STEPS TAKEN AND THE RESULTS FOR THE YEAR, AND CONFIRMS THAT NOTHING HAS BEEN BROUGHT TO HER ATTENTION DURING THE YEAR WHICH WOULD REQUIRE FURTHER EXAMINATION OF THE CURRENT CONFLICT OF INTEREST CERTIFICATIONS. THIS REVIEW IS INCLUDED AS PART OF THE COMMITTEE'S NORMAL REPORT TO THE BOARD REGARDING THE COMMITTEE'S ACTIVITIES. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE COMPLETES A PERFORMANCE EVALUATION AND ASSESSMENT OF SALARY FOR THE EXECUTIVE DIRECTOR ANNUALLY. THE EXECUTIVE COMMITTEE CONSISTS OF THE CHAIRMAN OF THE BOARD, CHAIRMAN OF THE RESEARCH ADVISORY COMMITTEE AND THE EXECUTIVE DIRECTOR. THE EXECUTIVE DIRECTOR IS A MEMBER OF THE EXECUTIVE COMMITTEE; HOWEVER, HAS NO VOTE WHEN IT COMES TO PERSONAL PERFORMANCE AND SALARY. THE ORTHOCAROLINA RESEARCH INSTITUTE SHARES HUMAN RESOURCE SERVICES WITH ORTHOCAROLINA, PA. THE ORTHOCAROLINA, PA HUMAN RESOURCE DEPARTMENT PERFORMS PERIODIC REVIEWS OF ALL POSITIONS TO ENSURE SALARIES ARE COMPETITIVE AND FAIR WITHIN THE MARKET. IT IS COMMON PRACTICE FOR SALARIES TO INCREASE 3-5% DEPENDING ON INDIVIDUAL PERFORMANCE ANNUALLY. THE EXECUTIVE DIRECTOR BUDGETS SALARY INCREASES ANNUALLY AND SHOULD A STAFF SALARY INCREASE GREATER THAN THE 3-5% EXPECTED RANGE, IT IS PRESENTED BEFORE THE EXECUTIVE COMMITTEE FOR APPROVAL. ALL SALARY ADJUSTMENTS MADE BY THE ORTHOCAROLINA RESEARCH INSTITUTE ARE DOCUMENTED AND SUBMITTED TO THE ORTHOCAROLINA PA, HUMAN RESOURCE DEPARTMENT FOR FINAL APPROVAL BEFORE SUBMITTING TO PAYROLL. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, POLICIES AND PROCEDURES AND FINANCIAL STATEMENTS ARE HELD IN THE OFFICE OF THE EXECUTIVE DIRECTOR. SUCH DOCUMENTS ARE AVAILABLE FOR REVIEW UPON REQUEST.